Latest Imagion Biosystems (ASX:IBX) News

Clinical setbacks and cash shortages weighed on healthcare shares, while selected companies advanced on sales, regulatory and patent news.
Investors now face a simple test: which businesses can turn their latest announcements into funded operations and revenue?

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

Imagion Biosystems has signed key CRO work orders and completed manufacturing of its MagSense HER2 Imaging Agent, advancing its Phase 1b/2 clinical trial targeting HER2+ breast cancer. Trial initiation is underway with seven prospective sites, including contract talks with the first US clinical site.

Big moves came from small and mid-cap names tied to drilling, project studies and fresh funding. Healthcare, mining and takeover stocks all had a busy week, but not every strong announcement held its gains.

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.